$1.27
Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
Innovent licenses IBI355 rights to Spero for up to $1.1bn
J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing
Overview
52-week range
$1.80
$3.22
0% of range
Avg surprise (last 2)
+73.3%
Avg reaction (last 2)
+4.6%
50% positive
Latest IV / EM
688%
EM ±157.5% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.13 | — | — | +48.0% | -3.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.03 | $-0.38 | +92.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.25 | $-0.55 | +54.5% | — | +13.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.32 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.33 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.06 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | — | -$0.03 |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $258,000 | — | $5M | $14M | $6M | — | $13M | $10M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-8M | — | $-8M | $-2M | $-15M | — | $-19M | $-19M |
| Net income | $-7M | — | $-7M | $-2M | $-14M | — | $-17M | $-18M |
| EPS (diluted) | $-0.13 | — | $-0.13 | $-0.03 | $-0.25 | — | $-0.32 | $-0.33 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $56M | $40M | $49M | $31M | $49M | $53M | $76M | $64M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $58M | $67M | $52M | $59M | $75M | $107M | $132M | $122M |
| Total assets | $59M | $69M | $54M | $62M | $78M | $111M | $135M | $150M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $6M | $10M | $28M | $29M | $44M | $64M | $70M | $69M |
| Total equity | $53M | $59M | $26M | $33M | $34M | $46M | $66M | $80M |